Does NIKI pay a dividend and is it safe?

Niki BioSolutions Inc. (NIKI) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Industrials / NIKI / dividends

UCAR (19) RETO (21) XPON (33) DFLI (25) ⌘ Pro Terminal →

Niki BioSolutions Inc. (NIKI) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is NIKI trading relative to its 50-day, 200-day, and 52-week technical levels?

NIKI last traded at $1.69 (-4.52% on volume of 25,520 shares), positioning the stock -61.33% below its 50-day simple moving average ($4.37) and -77.85% below its 200-day simple moving average ($7.63). Across its 52-week range of $1.70 to $17.20, NIKI sits at the 0.0% percentile with a 14-day RSI of 25.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.48 to $1.90).

$1.69 -4.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.67

Niki BioSolutions Inc. (NIKI) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $5.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NIKI Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NIKI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Niki BioSolutions Inc. (NASDAQ: NIKI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.69 (-4.52% 1D, market cap $5.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 486 tracked Industrials issuers, NIKI ranks #393 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NIKI compare to UCAR and RETO in the Industrials sector?

▼

Within the Industrials sector (Industrial Machinery/Components), NIKI carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -5.9%. By comparison, UCAR (U Power Limited (Class A)) holds a E grade (19/100 RQD, P/E N/A, ROIC -18.5%, cap $5.3M) and RETO (ReTo Eco-Solutions Inc. (Class A)) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $4.2M). Among the 5-stock peer group, NIKI leads on earnings multiple (N/A) while NIKI leads on capital efficiency (-5.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NIKI?

▼

Per NIKI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001734005), Niki BioSolutions Inc. generated $7.9M in revenue (+15.9% YoY), -$1.4M in net income, and -$1.8M in free cash flow against $18.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Industrials with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.67 (-1.00%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NIKI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY NIKI SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (31% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 25 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.63-22.8% Next Q

Q2 (-2Q)

Grade E$2.03-5.4% Next Q

Q3 (-1Q)

Grade E$1.92-12% Next Q

Current

Grade E$1.69-9.2% Hist 90D α

Trajectory: D (40) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NIKI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NIKI currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Industrials with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.37) and Max Pain ($1.77) forces dealer call-delta covering toward $18.06.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NIKI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NIKI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NIKI)

✓Walkthrough of NIKI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NIKI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -79.88%▼ SUPPORT BREAKDOWN

2026-11-03O $1.96H $1.96L $1.69C $1.69VOL 10.0K

RES: $6.59SUP: $2.39SMA50: $4.37SMA200: $7.63

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NIKI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NIKI Butterfly Map → + Track NIKI →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +15.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NIKI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NIKI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NIKI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NIKI)

Industrials Rank #393 of 486 ⚔️ UCAR vs NIKI Full Matrix →

1. Head-to-Head Industrials Peer Comparison (NIKI vs. UCAR, RETO, XPON, DFLI)

Industry: Industrial Machinery/Components (208 Tracked Issuers)

Across 486 tracked Industrials securities in the Roarable RQD universe, Niki BioSolutions Inc. (NIKI) ranks #393 by composite RQD confidence (32/100, grade E) and #461 by equity capitalization ($5.2M). Within this direct 5-issuer industry benchmark cohort, NIKI leads on earnings valuation at N/A trailing P/E, while NIKI leads on capital efficiency and profitability with -5.9% ROIC and — gross margin. XPON currently holds the highest overall quantitative score in the immediate peer group at 33/100 (E) compared with NIKI at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NIKI ACTIVE Niki BioSolutions Inc.	E	32/100	—	—	-5.9%	-4.52%	$5.2M	Benchmark Subject
UCAR U Power Limited (Class A)	E	19/100	—	36.3%	-18.5%	+4.69%	$5.3M	/ucar-vs-niki →
RETO ReTo Eco-Solutions Inc. (Class A)	E	21/100	—	35.3%	-35.0%	-6.59%	$4.2M	/reto-vs-niki →
XPON Expion Energy Inc.	E	33/100	—	13.9%	-35.0%	+1.96%	$3.6M	/xpon-vs-niki →
DFLI Dragonfly Energy Holdings Corp. (NV)	E	25/100	—	26.7%	-35.0%	-4.21%	$3.6M	/dfli-vs-niki →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001734005 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Niki BioSolutions Inc. (NIKI) reported GAAP revenue of $7.9M (+15.9% vs. FY2024 revenue of $6.8M , and +1719.8% cumulative change since FY2023) , GAAP net income of -$1.4M, operating cash flow of -$1.8M, and free cash flow of -$1.8M (-54.4% YoY). On the balance sheet, NIKI closed FY2025 with $18.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$7.9M	-$1.4M	-$1.8M	-$1.8M	$18.7M	—
FY2024 (FY)	2024-12-31	$6.8M	-$4.3M	-$1.2M	-$1.2M	$16.1M	—
FY2023 (FY)	2023-12-31	$431.4K	-$2.8M	-$7.7M	-$7.7M	—	—

3. NIKI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NIKI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NIKI compare to UCAR and RETO in the Industrials sector?

What are the biggest fundamental strengths and SEC risk factors for NIKI?

Where is NIKI trading relative to its 50-day, 200-day, and 52-week technical levels?

NIKI last traded at $1.69 (-4.52% on volume of 25,520 shares), positioning the stock -61.33% below its 50-day simple moving average ($4.37) and -77.85% below its 200-day simple moving average ($7.63). Across its 52-week range of $1.70 to $17.20, NIKI sits at the 0.0% percentile with a 14-day RSI of 25.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.48 to $1.90).

Direct Sub-Reports: NIKI RQD Cockpit NIKI 12M Forecast NIKI Earnings & Move NIKI Dividends & DRIP NIKI Insiders & 13F NIKI Whale Options NIKI Profit Sankey NIKI News & Why

ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ SEC XBRL & RQD VERIFIED

NIKI — Niki BioSolutions Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Niki BioSolutions Inc. (NIKI) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.69 (-4.52% 1D, market capitalization $5.2M).

Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -5.9%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Niki BioSolutions Inc. Is a NASDAQ-listed issuer classified in the Industrials sector, Industrial Machinery/Components industry. Per the recent news wire, the company has announced a supply agreement for APOE genotyping with Charter Research, indicating a genetic testing product offering.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Niki BioSolutions Inc. (NIKI) reported $7.9M in annual revenue (up from $6.8M in FY2024, +15.9% YoY) and -$1.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($431.4K revenue, -$2.8M net income) through FY2025, NIKI scaled operating cash flow to -$1.8M and free cash flow to -$1.8M, backed by $18.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Industrials with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.70 – $17.20 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlation analysis are — The only observable cross-reference is that the sector classification (Industrials) does not align with the genetic-testing activity described in the news wire, which a prospective investor should keep in mind when assessing the business and its comparables.

Key Question #1: Can NIKI sustain or expand its — operating margin and -5.9% ROIC against Industrial Machinery/Components peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $7.9M and free cash flow of -$1.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is NIKI's equity valuation to Industrials capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NIKI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Niki BioSolutions Inc. (NIKI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NIKI Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 21h ago

Niki BioSolutions Launches $1.396 Million ATM Equity Program With H.C. Wainwright

TradingView report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research

Yahoo Finance report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Niki BioSolutions (Nasdaq:NIKI) - Stock Analysis

Simply Wall St report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Titan • 1d ago

A genetic test tied to Alzheimer’s risk can now use urine, plasma or dried blood spots

Stock Titan report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com UK • 1d ago

Form 4 Niki BioSolutions: Kira Sheinerman (Director, 10% Owner) For: 22 July

Investing.com UK report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Tuesday's After-Market Session - XORTX Therapeutics (NASDAQ:XRTX), Edesa

Benzinga report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com Canada • 1d ago

Niki BioSolutions receives New York approval for expanded APOE test By Investing.com

Investing.com Canada report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo • 8d ago

Niki BioSolutions Announces New York State Approval for Its APOE Genotyping Test Using Dried Blood Spots, Plasma, and Urine

NYSDOH CLEP approval extends validated APOE genotyping beyond blood, buccal swab, saliva, and tissue for clinical and research use NEW HAVEN, CT and PRINCETON, NJ, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NIKI Bull vs. Bear Conversation Board — What's Your Call at $1.69?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NIKI 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $2.11 (+19.2%)

📌 Pinned Debate

Recent news flow includes a commercial supply agreement for APOE genotyping with Charter Research and $3.5M of reported FY 2025 cash, w

Don't sleep on NIKI's setup in Industrials. Recent news flow includes a commercial supply agreement for APOE genotyping with Charter Research and $3.5M of reported FY 2025 cash, which provides some runway for the company's operations.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (32/100) backs up the fundamental quality.

RetailWhale_TX 🐂 BULL

@ShortSeller_Dan Shorting a 3/20 institutional whale-flow stock at $1.77 is dangerous when funds are rotating into Industrials.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $1.47 (-16.9%)

Spot @ $1.77

Reported net losses in every period, negative free cash flow, 0% margins, ROIC of -5.9%, and a Piotroski F-Score of 1/9 point to weak f

Fading this rally in NIKI at $1.77. Reported net losses in every period, negative free cash flow, 0% margins, ROIC of -5.9%, and a Piotroski F-Score of 1/9 point to weak fundamentals while a new ATM equity program raises dilution risk.. With a beta of 1.0 and the stock sitting at $1.77 (52-wk range $1.70–$17.20), the easy multiple expansion is already priced in.